login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

Carotid stenting in asymptomatic patients: To do or not to do?


Thursday, 08 Mar 2012 16:40
David Sacks
David Sacks


By David Sacks


With regard to carotid stenting of asymptomatic patients, how is it that so many people can analyse the same data and draw such differing conclusions? In the United States, Medicare convened a panel of experts from professional societies to discuss whether carotid stenting is an appropriate treatment for asymptomatic carotid stenosis. Opinions ranged from definitely and unequivocally “yes” to equally emphatic “no”.

 

While carotid endarterectomy has been proved effective in preventing stroke in asymptomatic patients, the trials are ancient in terms of best medical therapy. Best medical therapy, with optimal (rather than routine) control of lipids, blood pressure, diabetes, and smoking, continues to improve but it is unlikely to reduce the stroke risk of an asymptomatic stenosis to zero. Therefore there should be a benefit to revascularisation, if performed with minimal morbidity and reasonable expense.

 

Comparing carotid stenting vs. carotid endarterectomy, CREST (Carotid revascularization endarterectomy vs. stenting trial) reported that the 30-day stroke/death rate for asymptomatic patients was 2.5% for carotid stenting vs. 1.4% for carotid endarterectomy. If post procedure myocardial infarction was included, carotid stenting and carotid endarterectomy had comparable outcomes, but it is unclear if myocardial infarction is a relevant outcome. It is a marker for long-term mortality, but it is possible that an asymptomatic “chemical” myocardial infarction does not necessarily cause increased mortality but instead simply indicates significant underlying coronary disease that itself causes late mortality. For symptomatic patients, the ICSS (International carotid stenting study) similarly showed roughly double the risk of stroke/death from carotid stenting as compared to carotid endarterectomy, as have analyses from national databases and from the Society for Vascular Surgery (SVS) carotid revascularisation registry. Furthermore, carotid stenting is significantly more expensive than carotid endarterectomy.

 

These data suggest that carotid stenting should not be performed if carotid endarterectomy is an option, and perhaps not performed at all if carotid stenting cannot meet the improved outcomes from best medical therapy. However, CREST also showed that stroke/death was far less common in the second half of the study, suggesting that truly contemporary carotid stenting outcomes easily match carotid endarterectomy and beat best medical therapy. In addition, cranial nerve injuries occur in about 5% of carotid endarterectomy patients. From a patient’s perspective it does not matter if a neurologic deficit was caused by a central or peripheral nerve injury. Most cranial nerve injuries are minor and resolve with time, but so do most minor strokes. If cranial nerve injuries were included in the 30-day stroke/death statistics carotid stenting and carotid endarterectomy would be comparable, although carotid stenting still has a higher mortality rate.


The results of CREST may not be generalisable. CREST recruited highly experienced operators with proven good outcomes and rejected half of the physicians who applied. Despite this selection, it was only after six years and half the patients had been enrolled that morbidity dropped. In ICSS, the physician could be performing his first case, albeit with a proctor, and could operate independently after 10 cases. ICSS is likely more representative of general practice and demonstrated carotid stenting outcomes for symptomatic patients that did not meet acceptable benchmarks. The learning curve reported in CREST was confirmed in ICSS and other studies. ICSS reported that centres treating <50 patients had 30-day stroke/death/myocardial infarction rate of 10% vs 5.9% for centres treating >50 patients. CAPTURE 2 (Carotid Acculink/Accunet post approval trial to uncover rare events) reported a facility threshold of 72 cases to consistently achieve a stroke/death rate rate <3%. An analysis of Medicare data from nearly 25,000 procedures reported the mean annual operator volume was only three carotid stenting cases/year. Low volume operators (<six carotid stenting cases/year) had nearly double the mortality (2.5% vs. 1.4%) of high volume operators (>24 carotid stenting /year).


The concern about lack of generalisability of good outcomes is being addressed in the US through independent accreditation of carotid stent facilities which requires meeting the American Heart Association thresholds of 30-day stroke/death rate of 3%/6% for asymptomatic/symptomatic patients. Outcomes-based accreditation is available through the ICACSF (www.icacsf.org) or ACE (bit.ly/wzj6US) but at the time of writing is not required by Medicare.

 


Should asymptomatic patients be treated with carotid stenting? It depends on how good the carotid stenting and endarterectomy operators are outside of trials, but more importantly, it depends on the outcomes from truly best medical therapy. These outcomes determine whether or not the procedure is suitable for reimbursement. The final answer to this question will probably end up depending on the proposed CREST 2 trial comparing best medical therapy to carotid stenting and carotid endarterectomy.

 

David Sacks is past president of the Society of Interventional Radiology (SIR) and president of the Intersocietal Commission for the Accreditation of Carotid Stent Facilities (ICACSF)





Add New Comment

Related Items


Most popular


OVER analysis: Endoleak does not predict reduced long-term survival but negatively impacts sac regression
Wednesday, 18 Jun 2014
An analysis of the OVER trial presented at the Society for Vascular Surgery Vascular Annual Meeting (SVS, 5–7 June, Boston, USA) shows that the development of endoleaks were common in patients ... OVER analysis: Endoleak does not predict reduced long-term survival but negatively impacts sac regression

Medtronic to acquire Covidien for US$42.9 billion in cash and stock
Monday, 16 Jun 2014
The acquistion creates a medical technology and services company with a comprehensive product portfolio and broad global reach. Medtronic to acquire Covidien for US$42.9 billion in cash and stock

FDA advisory panel unanimously recommends approval for Lutonix DCB
Friday, 13 Jun 2014
Lutonix DCB is one step closer to becoming the first US FDA-approved drug-coated balloon for the treatment of patients with femoropopliteal occlusive disease. FDA advisory panel unanimously recommends approval for Lutonix DCB

Features


The 11th Scientific Meeting of the Chinese Society of Interventional Radiology successfully held in Changsha
Tuesday, 08 Jul 2014
The 11th Scientific Meeting of the Chinese Society of Interventional Radiology (2014 CSIR) was held from 11–15 June 2014 in Changsha, Hunan Province, China. The Chinese Society of Interventional R... The 11th Scientific Meeting of the Chinese Society of Interventional Radiology successfully held in Changsha

Pressure-directed embolotherapy using antireflux devices to perform liver directed regional therapy
Tuesday, 08 Jul 2014
Unintended non-target delivery of embolic agents into any of the various hepaticoentric arteries that course from an intrahepatic artery to implant into an extra hepatic organ such as the stomach or ... Pressure-directed embolotherapy using antireflux devices to perform liver directed regional therapy

Profiles


Bien Soo Tan
Friday, 16 May 2014
Bien Soo Tan, senior consultant, Department of Diagnostic Radiology, Singapore General Hospital, S... Bien Soo Tan

James B Spies
Friday, 16 May 2014
The evolution of embolization over the past decade has been remarkable and it has fundamentally ... James B Spies

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions